Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
US10324088B2 · kind B2 · utility
8Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2017 |
| Grant date | Jun 18, 2019 |
| Priority date | — |
| Expiry date | May 22, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn's disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-α4β7 integrin drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.